ALK and non-small cell lung carcinoma: Obtaining clinically relevant ALK-positive material for validation is challenging; for example, out of 82 NSCLC cases tested for ALK rearrangements within Molecular Pathology in 2017, approximately 1% would test positive for ALK rearrangements.